Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and potassium ion efflux, leading to inhibition of protein, DNA, and RNA synthesis, and bacterial cell death.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Complicated skin and skin structure infections (c SSSI) in adults,Staphylococcus aureus bloodstream infections (bacteremia) including right-sided infective endocarditis,Off-label: Prosthetic joint infections, osteomyelitis, vancomycin-resistant enterococcal infections
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
4-6 mg/kg intravenously every 24 hours. For Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis, 6 mg/kg intravenously every 24 hours.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life: approximately 8-9 hours in patients with normal renal function; prolonged in renal impairment (up to 28 hours in severe impairment).
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Metabolism is not well characterized; minor hepatic metabolism suspected. Primarily excreted renally as unchanged drug.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily renal (78% unchanged in urine); biliary/fecal excretion is negligible (<6%).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
92-93% bound to human plasma proteins, primarily albumin.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.1 L/kg; low Vd indicating limited tissue distribution, primarily confined to extracellular fluid.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Not applicable (intravenous only; bioavailability is 100% by IV route).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Cr Cl ≥30 m L/min: no adjustment. Cr Cl <30 m L/min: 4-6 mg/kg intravenously every 48 hours. For patients on hemodialysis or continuous ambulatory peritoneal dialysis, administer after dialysis on dialysis days.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not studied in severe hepatic impairment (Child-Pugh Class C).
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Children 1-6 years: 10 mg/kg intravenously every 24 hours. Children 7-17 years: 7 mg/kg intravenously every 24 hours. Maximum dose: 500 mg per dose.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
No specific dose adjustment based solely on age. Use caution due to increased risk of renal impairment; adjust dose based on creatinine clearance as for adults.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Eosinophilic pneumonia: Monitor for new onset fever, dyspnea, cough, and pulmonary infiltrates.,Peripheral neuropathy: Monitor for sensory or motor deficits.,Clostridioides difficile-associated diarrhea: Consider if diarrhea occurs.,Skeletal muscle effects: Monitor creatine phosphokinase (CPK) levels weekly; discontinue if marked elevation or myopathy symptoms.,Renal impairment: Dose adjustment required for Cr Cl <30 m L/min.,Anaphylaxis/hypersensitivity reactions: Discontinue if severe reactions occur.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Known hypersensitivity to daptomycin or any component of the formulation.
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No clinically significant food interactions. Take without regard to meals.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at systemic exposures up to 4 times the human dose. Risk cannot be ruled out; use only if clearly needed.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Unknown if daptomycin is excreted in human milk. Caution advised due to potential disruption of infant gut flora. No M/P ratio available.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No specific dose adjustments recommended based on pharmacokinetic changes in pregnancy; standard dosing based on renal function and indication.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Monitor creatine phosphokinase (CPK) weekly due to risk of myopathy; daptomycin is inactivated by pulmonary surfactant, so avoid use in pneumonia. Administer over 30 min IV. Dose adjustment required for Cr Cl <30 m L/min (including hemodialysis).
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Report unexplained muscle pain, tenderness, or weakness immediately.,Complete the full course of therapy even if you feel better.,Inform your doctor if you have kidney disease or are on dialysis.,This medication is given intravenously; you may experience injection site reactions.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Concurrent use of rosuvastatin and daptomycin may increase the risk of skeletal muscle toxicity, particularly myopathy and rhabdomyolysis. Daptomycin can elevate serum creatine kinase (CK) levels and cause myopathy, while rosuvastatin, a potent HMG-CoA reductase inhibitor, also carries a risk of myotoxicity. The combination may synergistically enhance muscle damage, leading to potentially severe clinical outcomes."
"Concomitant use of pravastatin, a HMG-CoA reductase inhibitor, with daptomycin, a cyclic lipopeptide antibiotic, may increase the risk of skeletal muscle toxicity, including myopathy and rhabdomyolysis. This is due to additive or synergistic effects on skeletal muscle cells, potentially leading to elevated creatine kinase (CK) levels and muscle pain or weakness. Clinically, this interaction can result in severe muscle damage, renal impairment from myoglobinuria, and in rare cases, life-threatening rhabdomyolysis."
"The combination of fluvastatin, an HMG-CoA reductase inhibitor, and daptomycin, a lipopeptide antibiotic, may increase the risk and severity of myopathy and rhabdomyolysis due to additive muscle toxicity. Daptomycin can cause skeletal muscle effects such as elevated creatine kinase (CK) and myalgia, while statins are known to induce myopathy via mitochondrial dysfunction and altered cellular signaling. Concurrent use may potentiate these effects, leading to serious clinical outcomes including renal failure."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DAPTOMYCIN IN 0.9% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and potassium ion efflux, leading to inhibition of protein, DNA, and RNA synthesis, and bacterial cell death.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DAPTOMYCIN IN 0.9% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DAPTOMYCIN IN 0.9% SODIUM CHLORIDE is: 4-6 mg/kg intravenously every 24 hours. For Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis, 6 mg/kg intravenously every 24 hours.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DAPTOMYCIN IN 0.9% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DAPTOMYCIN IN 0.9% SODIUM CHLORIDE is classified as Category A/B. No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at systemic exposures up to 4 times the human dose. Risk cannot be ruled ou. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.